Aldeyra Therapeutics (ALDX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Voting matters and shareholder proposals
Election of one Class III Director, with Todd C. Brady, M.D., Ph.D. nominated for the position.
Ratification of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026.
Advisory vote to approve the compensation of named executive officers.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all proposals presented at the annual meeting.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Aldeyra Therapeutics
- Proxy covers director election, auditor ratification, and say-on-pay, with strong governance focus.ALDX
Proxy filing27 Apr 2026 - Net loss decreased to $33.8M in 2025; FDA decision on reproxalap and AbbVie option remain key catalysts.ALDX
Q4 202527 Feb 2026 - Reproxalap nears FDA decision, targeting rapid relief in dry eye and allergy with AbbVie partnership.ALDX
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - RASP modulator pipeline advances with key milestones and strong financials for 2024–2025.ALDX
Status Update3 Feb 2026 - Reproxalap met its Phase 3 endpoint, enabling NDA resubmission and potential commercial partnership.ALDX
Study Update2 Feb 2026 - Late-stage dry eye trials, AbbVie partnership, and diverse pipeline drive near-term catalysts.ALDX
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - NDA resubmission for rapid-acting dry eye therapy is imminent, with robust pipeline progress.ALDX
H.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026 - Lead drug for dry eye nears FDA decision, with AbbVie partnership and broad pipeline expansion.ALDX
Jefferies London Healthcare Conference 202412 Jan 2026 - Late-stage eye drug developers outlined novel therapies and 2024 launch milestones.ALDX
Citi's 2024 Global Healthcare Conference11 Jan 2026